Skip to content


Journal for ImmunoTherapy of Cancer

Open Access

Adoptive TIL in HPV-negative oral scca

  • Rom Leidner1,
  • Brendan D Curti2,
  • Roxanne M Payne2,
  • Walter Urba1, 2, 3,
  • Keith S Bahjat1, 2, 3,
  • Yoshinobu Koguchi1,
  • Krista Nelson2,
  • Jennifer A Moore2,
  • Marka Crittenden1, 4,
  • Yedeh Ying2, 5,
  • Ashish Patel2, 6,
  • Allen Cheng2, 5,
  • Tuan G Bui2, 5,
  • Traci Hilton6,
  • Christopher Paustian1,
  • Sachin Puri1,
  • Hong Ming Hu1,
  • Carlo Bifulco1,
  • Zipei Feng1, 2, 3,
  • R Bryan Bell2, 5 and
  • Bernard Fox1
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P26

Published: 4 November 2015


ImiquimodElective Neck DissectionOral TongueContralateral NeckPartial Glossectomy


A 22 year old male was diagnosed with clinical T2 squamous cell carcinoma of the lateral oral tongue. He underwent partial glossectomy with elective neck dissection of ipsilateral cervical nodes levels I-IV. Pathology showed a 2.1cm primary tumor with clear margins to 5mm, 1.6cm depth of invasion, one of 23 lymph nodes with a 3.5mm focus of involvement at level II, sans extra-capsular extension (pT2 pN1 M0).


Through an institutional research tissue protocol, a primary cell line was successfully established. TIL were simultaneously cultured and demonstrated tumor specific IFN-γ production. He completed a course of adjuvant IMRT to 60Gy in the ipsilateral neck and 54Gy in the contralateral neck within 12 weeks of surgery, without complications.


Three months following completion of radiation, bilateral neck nodal recurrence was noted on scans and confirmed by biopsy (month 6 of disease course, overall). He was treated first line chemotherapy for recurrent disease during months 7 to 10, progressing locally in the neck through two multi-drug regimens (cisplatin/cetuximab/5FU, carboplatin/docetaxel). He then enrolled on a Phase Ib trial of combination anti-PD-1/anti-KIR during months 11 to 14 (BMS CA223-001, nivolumab/lirilumab), again progressing locally in the bilateral neck. At month 15, an individual patient compassionate treatment protocol was approved (FDA IND #16279, PH&S IRB #14-323B), using reduced-intensity Cy/Flu preparative lymphodepletion followed by adoptive transfer of expanded autologous TIL in conjunction with DC-targeted microvessicle DPV-001 intradermal vaccine (DRibbles) and imiquimod adjuvant, with high-dose IL-2 support. Peripheral immune monitoring was performed using whole blood time-course sampling. Multi-spectral immunofluorescence with digital image quantitative immunophenotyping of FFPE longitudinal biopsy specimens was performed using the PerkinElmer Vectra® platform. Data and results analysis will be presented in poster format.



Providence Portland Medical Foundation, Harder Family, Robert W. Franz, Lynn and Jack Loacker, Providence Health & Services, UbiVac and Prometheus Labs.

Authors’ Affiliations

Earl A. Chiles Research Institute, Providence Cancer Center, Portland, USA
Providence Cancer Center, Providence Portland Medical Center, Portland, USA
Robert W. Franz Cancer Research Center, Portland, USA
The Oregon Clinic, Portland, USA
Head & Neck Institute, Portland, USA
UbiVac, Portland, USA


© Leidner et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.